ERBB2 and breast carcinoma: HER2 amplification, characterized by an increase in the number of HER2 gene copies, has been reported in approximately 2–5% of NSCLC cases [10,13,19,23], which is a rather low rate as compared to breast cancer (approximately 20–30% of cases [25]).